FRANKLIN LAKES, N.J., Sept. 7 /PRNewswire-FirstCall/ -- Medco Health Solutions, Inc. (NYSE: MHS) announced today that it has agreed to sell $500 million aggregate principal amount of 2.750% senior notes due September 15, 2015 and $500 million aggregate principal amount of 4.125% senior notes due September 15, 2020 in an underwritten public offering. Deutsche Bank Securities Inc. and Goldman, Sachs & Co. are acting as representatives of the several underwriters.
Medco intends to use the net proceeds from the offering for general corporate purposes, including repayment of borrowings under its senior unsecured revolving credit facility, which may include borrowings used to fund its previously announced acquisition of United BioSource Corporation. The offering is expected to close on September 10, 2010. The prospectus supplement and accompanying prospectus related to the offering of the notes may be obtained by contacting: Deutsche Bank Securities Inc.Prospectus Department100 Plaza One, Floor 2Jersey City, New Jersey 07311-3901, Toll-free: 1-800-503-4611 Email to firstname.lastname@example.org Goldman, Sachs & Co.Prospectus Department200 West StreetNew York, NY 10282Toll-free: 1-866-471-2526Facsimile: 1-212-902-9316 Email to email@example.com Electronic copies of the prospectus supplement and accompanying prospectus are also available on the Securities and Exchange Commission Web site at www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About MedcoMedco Health Solutions, Inc. (NYSE: MHS) is pioneering the world's most advanced pharmacy® and its clinical research and innovations are part of Medco making medicine smarter™ for approximately 65 million members.
With more than 20,000 employees dedicated to improving patient health and reducing costs for a wide range of public and private sector clients, and 2009 revenues of nearly $60 billion, Medco ranks 35th on the Fortune 500 list and is named among the world's most innovative, most admired and most trustworthy companies.
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about the business and future financial results of the pharmacy benefit management ("PBM") and specialty pharmacy industries, and other legal, regulatory and economic developments. We use words such as "anticipates," "believes," "plans," "expects," "projects," "future," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue," "guidance" and similar expressions to identify these forward-looking statements. Medco's actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors.
|SOURCE Medco Health Solutions, Inc.|
Copyright©2010 PR Newswire.
All rights reserved